Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine

Antimicrob Agents Chemother. 1996 Apr;40(4):953-7. doi: 10.1128/AAC.40.4.953.

Abstract

We have selected and plaque purified a mutant of feline immunodeficiency virus (FIV) that is resistant to 2',3'-dideoxycytidine (ddC). This mutant was selected in cultured cells in the continuous presence of 25 microM ddC. The mutant, designated DCR-5c, was fourfold resistant to ddC, threefold resistant to 2',3'-dideoxyinosine, and more than fourfold resistant to phosphonoformic acid. DCR-5c displayed little or no resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine, 3'-azido-3'-deoxythymidine, or 9-(2-phosphonylmethoxyethyl) adenine. Reverse transcriptase purified from DCR-5c was less susceptible to inhibition by ddCTP, phosphonoformic acid, ddATP, or azido-dTTP than the wild-type FIV reverse transcriptase. Sequence analysis of DCR-5c revealed a single base change (G to C at nucleotide 2342) in the reverse transcriptase-encoding region of FIV. This mutation results in substitution of His for Asp at codon 3 of FIV reverse transcriptase. The role of this mutation in ddC resistance was confirmed by site-directed mutagenesis.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antiviral Agents / pharmacology*
  • Base Sequence
  • Cats
  • Cell Line
  • Didanosine / pharmacology
  • Drug Resistance, Microbial
  • Immunodeficiency Virus, Feline / drug effects*
  • Immunodeficiency Virus, Feline / genetics*
  • Molecular Sequence Data
  • RNA-Directed DNA Polymerase / genetics
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Zalcitabine / pharmacology*
  • Zidovudine / pharmacology

Substances

  • Antiviral Agents
  • Reverse Transcriptase Inhibitors
  • Zidovudine
  • Zalcitabine
  • RNA-Directed DNA Polymerase
  • Didanosine